Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2017

Dhingra P, Martinez-Fundichely A, Berger A, Huang FW, Forbes AN, Liu EM, et al. Identification of novel prostate cancer drivers using RegNetDriver: a framework for integration of genetic and epigenetic alterations with tissue-specific regulatory network. Genome Biol. 2017;18(1):141.

Gong Q, Wang C, Zhang W, Iqbal J, Hu Y, Greiner TC, et al. Assessment of T-cell receptor repertoire and clonal expansion in peripheral T-cell lymphoma using RNA-seq data. Sci Rep. 2017;7(1):11301.

Liapis H, Gaut JP, Klein C, Bagnasco S, Kraus E, Farris AB, et al. Banff Histopathological Consensus Criteria for Preimplantation Kidney Biopsies. Am J Transplant. 2017;17(1):140-150.

Muhlbauer A, Momtahen S, Mihm MC, Wang J, Magro CM. The correlation of the standard 5 probe FISH assay with melanocytic tumors of uncertain malignant potential. Ann Diagn Pathol. 2017;28:30-36.

De Robertis M, Loiacono L, Fusilli C, Poeta ML, Mazza T, Sanchez M, et al. Dysregulation of EGFR Pathway in EphA2 Cell Subpopulation Significantly Associates with Poor Prognosis in Colorectal Cancer. Clin Cancer Res. 2017;23(1):159-170.

Isella C, Brundu F, Bellomo SE, Galimi F, Zanella E, Porporato R, et al. Selective analysis of cancer-cell intrinsic transcriptional traits defines novel clinically relevant subtypes of colorectal cancer. Nat Commun. 2017;8:15107.

Fajgenbaum DC, Uldrick TS, Bagg A, Frank D, Wu D, Srkalovic G, et al. International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood. 2017;129(12):1646-1657.

Magro CM, Olson LC, Nguyen GH, de Feraudy SM. CD30 Positive Lymphomatoid Angiocentric Drug Reactions: Characterization of a Series of 20 Cases. Am J Dermatopathol. 2017;39(7):508-517.

Swendeman SL, Xiong Y, Cantalupo A, Yuan H, Burg N, Hisano Y, et al. An engineered S1P chaperone attenuates hypertension and ischemic injury. Sci Signal. 2017;10(492).

Solomon JP, Dell'Aquila M, Fadare O, Hasteh F. Her2/neu Status Determination in Breast Cancer: A Single Institutional Experience Using a Dual-Testing Approach With Immunohistochemistry and Fluorescence In Situ Hybridization. Am J Clin Pathol. 2017;147(4):432-437.